[Cytokines in the treatment of a generalized surgical infection].
A novel approach to the treatment of surgical sepsis has been tried: cytokine-based immunotherapy. Human recombinant interleukin-2 (IL-2) and a mixture of native cytokines obtained by arteriovenous perfusion of xenospleen were used as a source of proinflammatory cytokines. Extracorporeal immunotherapy of 62 patients with surgical sepsis with mononuclear cells treated by autologous IL-2 resulted in a significant decrease of endotoxicosis and effective immunocorrection. Cytokine-based immunotherapy notably decreased the mortality of patients with generalized surgical infection--to 14.6%, which was lower than the expected mortality (35%) and the mortality in the control group (34.5%).
Pal'tsev
A V
AV
Ovechkin
A V
AV
Zakharova
N F
NF
Rovina
A K
AK
Leplina
O Iu
OIu
Shevela
E Ia
EIa
Ostanin
A A
AA
Chernykh
E R
ER
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D016207:Cytokines / Q000627:therapeutic use*; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy / Q000379:methods; D007376:Interleukin-2 / Q000627:therapeutic use; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D018461:Soft Tissue Infections / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D016060:Sorption Detoxification / Q000379:methods; D013154:Spleen; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery
D016207:Cytokines; D007376:Interleukin-2; D011994:Recombinant Proteins